ProQR Therapeutics (NASDAQ:PRQR) Shares Up 13.5%

ProQR Therapeutics NV (NASDAQ:PRQR)’s share price shot up 13.5% during trading on Friday . The company traded as high as $9.66 and last traded at $9.07, 657,592 shares were traded during trading. An increase of 201% from the average session volume of 218,544 shares. The stock had previously closed at $7.99.

A number of research firms recently commented on PRQR. BidaskClub upgraded Misonix from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 3rd. ValuEngine upgraded Valmont Industries from a “sell” rating to a “hold” rating in a report on Friday. Finally, Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $28.67.

The company has a quick ratio of 10.08, a current ratio of 10.08 and a debt-to-equity ratio of 0.14. The stock has a fifty day moving average price of $10.58.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.05). Equities analysts expect that ProQR Therapeutics NV will post -1.65 earnings per share for the current fiscal year.

Large investors have recently modified their holdings of the company. Pura Vida Investments LLC boosted its holdings in shares of ProQR Therapeutics by 35.3% during the fourth quarter. Pura Vida Investments LLC now owns 76,827 shares of the biopharmaceutical company’s stock worth $1,212,000 after acquiring an additional 20,024 shares during the period. Northern Trust Corp bought a new stake in shares of ProQR Therapeutics during the fourth quarter worth approximately $666,000. Nikko Asset Management Americas Inc. bought a new stake in shares of ProQR Therapeutics during the first quarter worth approximately $4,016,000. Altrinsic Global Advisors LLC boosted its holdings in shares of ProQR Therapeutics by 9.8% during the first quarter. Altrinsic Global Advisors LLC now owns 199,060 shares of the biopharmaceutical company’s stock worth $2,761,000 after acquiring an additional 17,700 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of ProQR Therapeutics by 14.1% during the fourth quarter. Geode Capital Management LLC now owns 19,193 shares of the biopharmaceutical company’s stock worth $302,000 after acquiring an additional 2,375 shares during the period. Institutional investors own 61.75% of the company’s stock.

About ProQR Therapeutics (NASDAQ:PRQR)

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Further Reading: Penny Stocks

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.